Seagen loses arbitration ruling against Daiichi Sankyo

By Thomson Reuters Aug 12, 2022 | 12:39 PM

(Reuters) – Seagen Inc said on Friday an arbitrator had ruled in favor of Japan’s Daiichi Sankyo over an agreement between the two companies for using Seagen’s drug technology.

A Texas jury in April awarded Seagen nearly $42 million from Daiichi Sankyo over claims that Daiichi and AstraZeneca plc’s breast-cancer drug Enhertu violated Seagen’s patent rights.

(Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur)